Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados 42 (2) Autor MORALES,MARCELO M. (2) ALONSO,SILVIA DEL V. (1) FALKENSTEIN,DORIS (1) LOPES,ANÍBAL GIL (1) ROCCO,PATRICIA R.M. (1) SANTOS,RAQUEL S. (1) SILVA,ADRIANA L. DA (1) XISTO,DÉBORA G. (1) Mais... Palavra-chave Asthma (1) CFTR (1) Chloride channel (1) Kidney (1) Lung cancer (1) Nanotechnology (1) Nephron (1) Turberculosis (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2013 (1) 2000 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última The Cystic Fibrosis Transmembrane Regulator (CFTR) in the kidney 42 MORALES,MARCELO M.; FALKENSTEIN,DORIS; LOPES,ANÍBAL GIL. The cystic fibrosis transmembrane regulator (CFTR) is a Cl- channel. Mutations of this transporter lead to a defect of chloride secretion by epithelial cells causing the Cystic Fibrosis disease (CF). In spite of the high expression of CFTR in the kidney, patients with CF do not show major renal dysfunction, but it is known that both the urinary excretion of drugs and the renal capacity to concentrate and dilute urine is deficient. CFTR mRNA is expressed in all nephron segments and its protein is involved with chloride secretion in the distal tubule, and the principal cells of the cortical (CCD) and medullary (IMCD) collecting ducts. Several studies have demonstrated that CFTR does not only transport Cl- but also secretes ATP and, thus, controls other... Tipo: Info:eu-repo/semantics/article Palavras-chave: CFTR; Kidney; Nephron; Chloride channel. Ano: 2000 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652000000300013 Nanoparticle-based therapy for respiratory diseases 42 SILVA,ADRIANA L. DA; SANTOS,RAQUEL S.; XISTO,DÉBORA G.; ALONSO,SILVIA DEL V.; MORALES,MARCELO M.; ROCCO,PATRICIA R.M.. Nanotechnology is an emerging science with the potential to create new materials and strategies involving manipulation of matter at the nanometer scale (<100 nm). With size-dependent properties, nanoparticles have introduced a new paradigm in pharmacotherapy – the possibility of cell-targeted drug delivery with minimal systemic side effects and toxicity. The present review provides a summary of published findings, especially regarding to nanoparticle formulations for lung diseases. The available data have shown some benefits with nanoparticle-based therapy in the development of the disease and lung remodeling in respiratory diseases. However, there is a wide gap between the concepts of nanomedicine and the published experimental data and clinical... Tipo: Info:eu-repo/semantics/article Palavras-chave: Asthma; Turberculosis; Nanotechnology; Lung cancer. Ano: 2013 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652013000100137 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco